Pheon: advancing ADCs with first-in-class mAb, payload platform

Months after CEO Bertrand Damour steered NBE to a sale to Boehringer Ingelheim, he has assumed leadership of Pheon, a start-up seeking to advance an antibody-drug conjugate as well as a payload technology platform the company hopes it can improve from a prior attempt.

Pheon Therapeutics Ltd. revealed a $68 million series A round on Wednesday, with Brandon Capital, Forbion and Atlas Venture as co-leaders. Seed investor Research Corporation Technologies (RCT) also participated...